SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harold Engstrom who wrote (9118)1/16/2002 5:48:15 PM
From: Vector1   of 9719
 
Harold et all.

Thanks for your thoughts. To change gears I am thinking of buying CBST tomorrow at 18 or better at the open.

01/16 4:16P (DJ) +DJ Cubist Pharma Announces Results From Cidecin Trial
Story 9857 DJ Cubist Pharma Study -2: Shrs Halted At $31.75 >CBST
LEXINGTON, Mass. (Dow Jones)--Results from Cubist Pharmaceuticals Inc.'s
(CBST) first phase III trial of its antibiotic Cidecin didn't achieve the
primary endpoint of "demonstrating non-inferiority to an active comparator
agent."
In a press release Wednesday, the pharmaceutical company said it suspended
enrollment in the second phase III study examining the safety and
effectiveness of Cidecin in the treatment of community-acquired pneumonia
requiring hospitalization.
Cubist's shares were halted for news pending at $31.75.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News